Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling

SIMPLE SUMMARY: PARPi are approved as monotherapy agents and under advanced clinical investigation as a combination therapy for the treatment of cancer. We demonstrate for the first time that five of the approved PARPi vary in their ability to suppress cellular PARP activity after drug removal. Ruca...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Hannah L., Willmore, Elaine, Mukhopadhyay, Asima, Drew, Yvette, Curtin, Nicola J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688250/
https://www.ncbi.nlm.nih.gov/pubmed/36428653
http://dx.doi.org/10.3390/cancers14225559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688250/
https://www.ncbi.nlm.nih.gov/pubmed/36428653
http://dx.doi.org/10.3390/cancers14225559

Ejemplares similares